TY - JOUR T1 - Shared Decision Making for Patients Hospitalized with Acute Myocardial Infarction. A Randomized Trial JF - medRxiv DO - 10.1101/2022.02.17.22271131 SP - 2022.02.17.22271131 AU - Megan E. Branda AU - Marleen Kunneman AU - Alejandra I. Meza-Contreras AU - Nilay D. Shah AU - Erik P. Hess AU - Annie LeBlanc AU - Jane A. Linderbaum AU - Danika M. Nelson AU - Margaret R. Mc Donah AU - Carrie Sanvick AU - Holly K. Van Houten AU - Megan Coylewright AU - Sara R. Dick AU - Henry H. Ting AU - Victor M. Montori Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/02/18/2022.02.17.22271131.abstract N2 - Objective Adherence to guideline-recommended medications after acute myocardial infarction (AMI) is suboptimal. Patient fidelity to treatment regimens may be related to their knowledge of the risk of death following AMI, the pros and cons of medications, and to their involvement in treatment decisions. Shared decision making may improve both patients’ knowledge and involvement in treatment decisions.Methods In a pilot trial, patients hospitalized with AMI were randomized to the use of the AMI Choice conversation tool or to usual care. AMI Choice includes a pictogram of the patient’s estimated risk of mortality at 6 months with and without guideline-recommended medications, i.e., aspirin, statins, beta-blockers, and angiotensin-converting enzyme inhibitors. Primary outcomes were patient knowledge and conflict with the decision made assessed via post-encounter surveys. Secondary outcomes were patient involvement in the decision-making process (observer-based OPTION12 scale) and 6-month medication adherence.Results Patient knowledge of the expected survival benefit from taking medications was significantly higher (62% vs. 16%, p<0.0001) in the AMI Choice group (n=53) compared to the usual care group (n=53). Both groups reported similarly low levels of conflict with the decision to start the medications (13 (SD 24.2) vs. 16 (SD 22) out of 100; p=.16). The extent to which clinicians in the AMI Choice group involved their patients in the decision-making process was high (OPTION12 score 53 out of 100, SD 12). Medication adherence at 6-months was relatively high in both groups and not different between groups.Conclusions The AMI Choice conversation tool improved patients’ knowledge of their estimated risk of short-term mortality after an AMI and the pros and cons of treatments to reduce this risk. The effect on patient fidelity to recommended medications of using this SDM tool and of SDM in general should be tested in larger trials enrolling patients at high risk for nonadherence.Trial registration number NCT00888537Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT00888537Funding StatementThis study was funded by Mayo ClinicAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Mayo Clinic gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -